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Ovarian cancer is the commonest cause of death from gynae-
cological cancer in the developed world (Silverberg et al.,
1990; Booth & Beral, 1985). The age adjusted death rates
from ovarian cancer have continued to increase since 1955
(Silverberg et al., 1990). A major cause of the high mortality
rate from ovarian cancer is the late presentation of the
disease in over 60% of patients, with an associated 5-year
survival rate of approximately 5% (Ozols et al., 1980).
Several factors have been implicated in the aetiology of
ovarian cancer, including a genetic predisposition, reproduc-
tive history, smoking, infection with mumps virus, dietary
factors, and the use of talc (Piver, 1987). The most convinc-
ing factor to emerge as an influence on the development of
ovarian cancer is hormonal. Several studies have shown that
the risk of ovarian cancer in nulliparous women is 1.5-3.3
times greater than that of parous women (Silverberg et al.,
1990; Piver, 1987). The 'incessant ovulation' hypothesis pro-
posed initially by Fathalla (1971), and expanded by others
(Casagrade et al., 1979) attempted to explain the protective
effect of pregnancy as being due to the rest periods afforded
by pregnancy from incessant ovulation. The incessant ovula-
tion hypothesis is supported by the more common occurrence
of malignant change in the right ovary which ovulates more
frequently (Cruickshank, 1990). Cramer and Welch (1983)
suggested that whilst incessant ovulation led to the formation
of inclusion cysts, excessive and continued gonadotropin
stimulation contributed to malignant transformation by
trophic effects on ovarian epithelium. Thus, suppression of
gonadotropin release by oral contraceptives could explain the
decreased incidence of ovarian cancer in women taking oral
contraceptives. This hypothesis presents the case for the
involvement of another group of peptide cell regulators, the
cytokines, in the pathogenesis of ovarian cancer.
Cytokines are low molecular weight (<80 kDa) peptide
cell regulatory factors that have wide ranging effects on
different cell populations (Balkwill & Burke, 1989). Some
cytokines can directly or indirectly inhibit tumour growth
and have been used in cancer therapy (Balkwill, 1989). How-
ever, inappropriate cytokine activity has been implicated in
the pathogenesis of infectious, inflammatory and autoim-
mune diseases, and there is now increasing evidence that
cytokine production by tumours may contribute to the patho-
physiology of cancer. For example, interleukin-6 has been
shown to be an autocrine growth factor in myeloma, and
overproduction of IL-6 causes the systemic symptoms and
the immunological abnormalities in Castleman's disease
(Kishimoto, 1989). Tumour necrosis factor (TNF) has been
implicated in the suppression of haematopoesis in hairy cell
leukaemia, and in bone marrow necrosis in cancer patients
(Lindemann et al., 1989; Knupp, Pekala & Vornelius, 1988).
Experimental studies also suggest roles for cytokines in
cancer cachexia and the hypercalcaemia of cancer (Darling et
al., 1990; Sato et al., 1987).
Constitutive production of several cytokines by human
ovarian cancer cell lines and fresh tumour biopsy material
has been demonstrated. Naylor et al. (1990) have shown that
TNF mRNA and protein is expressed by ovarian tumour
cells in biopsies from patients with epithelial ovarian cancer.
In contrast, in the normal the rat and bovine ovary,
immunoreactive TNF has been detected in granulosa cells
and stromal macrophages, but not ovarian epithelium (Roby
& Terranova, 1989). Constitutive production of macrophage
colony stimulating factor (M-CSF) and expression of the
c-fms oncogene (encoding the M-CSF receptor) has been
demonstrated in human ovarian cancers and ovarian cancer
cell lines (Ramakrishnan et al., 1989; Kascinski et al., 1990),
but not in normal ovarian epithelium. Indeed, serial
measurements of serum M-CSF in patients with ovarian
cancer may be useful in monitoring disease activity (Kacinski
et al., 1989). A monocyte chemotactic factor produced by
ovarian cancer cell lines (Bottazzi et al., 1985), is now known
to be the TNF and IL-1 inducible cytokine monocyte
chemotactic protein (MCP-1) (Bottazzi et al., 1990).
Interleukin-6 production is transiently induced in
gonadotropin-primed hyperstimulated ovaries (Motro et al.,
1990), can be detected in the ascitic fluid of ovarian cancer
patients (Erroi et al., 1989), and is constitutively produced by
human ovarian cancers and ovarian cancer cell lines (Watson
et al., 1990). Interleukin-I has also been detected in a propor-
tion of human ovarian cancers by in situ hybridisation and
immunohistochemistry (unpublished observations). The pro-
found cell regulatory effects of cytokines at picomolar con-
centrations in vitro, suggest that the expression of cytokines
by human epithelial ovarian cancers may have an important
role in their in vivo pathophysiology.
Tumour necrosis factor has antitumour effects in murine
and human tumour xenograft models (Haranaka et al.,
1984). We have studied the effect of intraperitoneal TNF
administration in intraperitoneal human ascitic ovarian
cancer xenograft models (Malik et al., 1989). TNF therapy
prolonged survival in two out of three xenograft models, but,
paradoxically, restored the ability of all three non-TNF pro-
ducing ovarian tumours to form peritoneal tumour implants.
Exogenous TNF administration therefore led to a pathological
picture reminiscent of metastatic human ovarian cancer in
the xenograft models. To study the possible role of tumour
produced TNF on peritoneal implantation and invasion, the
behaviour of Chinese Hamster Ovary cells that had been
transfected with the human TNF gene (CHO/TNF cells) was
compared to CHO cells that contained the transfection vec-
tor alone (CHO/NEO cells) (Oliff et al., 1987). CHO/TNF
cells showed enhanced implantation to the surface of the
peritoneum and liver, and also metastasised to the lungs.
Furthermore, the metastatic capability of CHO/TNF cells
could be specifically abrogated by injection of antibodies to
TNF (Malik et al., 1990). Other studies in experimental
models have shown that TNF can enhance tumour metastasis
(Giavazzi et al., 1990). Properties of TNF that could
potentially contribute to promotion of metastasis include
stimulation of angiogenesis (Frater-Schroder et al., 1987),
enhancement of tumour cell adhesion to host cells (Rice et
al., 1988), and induction of tumour cell metalloproteinases
(Ito et al., 1990). The known procoagulant activities of TNF
(Pober, 1987), and the induction of platelet derived growth
factor (Hajjar et al., 1987), could contribute to the generation
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of tumour stroma, an important step in the establishment of
tumours in metastatic sites (Dvorak, 1986).
The other cytokines that are produced by ovarian cancers
are intimately associated with TNF in the cytokine network
(Balkwill & Burke, 1989). Interleukin-I and M-CSF both
induce TNF in monocytes and mesenchymal cells (Philip &
Epstein, 1986; Le & Vilcek, 1987; Warren & Ralph, 1986).
TNF induces the production of TNF, M-CSF, IL-1, IL-6,
and MCP-1 in several cell populations (Balkwill, 1989). Thus
there exists a potential self perpetuating cytokine induction
network in the vicinity of a tumour cell or a normal host cell
generating cytokines which can influence tumour biology.
For example IL-1 enhanced metastasis of melanoma cells
(Giavazzi et al., 1990), and promoted the peritoneal implant-
ation of human ovarian cancer xenografts (Malik et al. -
unpublished data). IL-6 has been reported to enhance the
motility of breast cancer cells, a property that is associated
with enhanced metastatic potential (Tamm et al., 1989). M-
CSF and MCP may contribute indirectly to metastasis by
recruiting macrophages to tumour sites. These could be a
further source of metastasis enhancing cytokines such as IL-1
and TNF, and secrete other factors that have growth stimu-
latory effects on ovarian cancer cells (Welander et al., 1982).
Can reasonable correlations be made between the effects of
cytokines in ovarian cancer models with some of the known
risk factors and prognostic indicators in ovarian cancer?
Figure 1 shows the potential sites of cytokine induced
tumour progression and the cytokines that could influence
these stages.
The damage involved in ovulation could lead to the local
release ofcytokines, such as TNF and TGF-,B by host macro-
phages, that contribute to the healing fibrotic response (Pos-
thelwaite & Seyer, 1990). Both these cytokines are capable of
inducing metalloproteinase production by tumour cells, and
increasing their invasive potential (Ito et al., 1990; Welch et
al., 1990). There is no evidence as yet that cytokines can
cause malignant transformation of normal epithelia, although
TNF can cause DNA strand damage in cells susceptible to its
cytotoxic effects. TNF also activates several putative
oncogenes including c-jun (Brenner et al., 1989) which is
overexpressed in some human ovarian tumours (De Greve et
al., 1990). Overexpression of the c-erbB-2 oncogene is an
adverse prognostic indicator in human ovarian cancer
Normal epithelium 19r TI ri @I* @
DNA STRAND DAMAGE ? ACTIVATION OFONCOGENES .TNF
Neoplatic
Transformation
STIMUL
Growth
ENZYME INDUCTION
INCREASEDADHERENCE TNF INCREASED MOTILITY TN
ICOAGULATION _ IL-1
_, X r TGF-BETA
Metastasis
Figure 1 Potential sites of cytokine interactions in ovarian
tumours.
(Slamon et al., 1989), and the similarity of the c-erbB-2
oncogene product to the epidermal growth factor receptor
suggests that an unidentified cytokine may be involved in
promoting ovarian cancer growth. Levels of c-erbB-2 oncogene
expression correlate with resistance to the cytocidal effects of
TNF (Hudziak et al., 1988). Although there is no evidence as
yet that TNF regulates c-erbB-2 expression, one could
speculate that c-erbB-2 positive tumours are TNF resistant
tumours that have emerged after prolonged exposure to
TNF.
Current evidence indicates that the normal ovarian surface
epithelium, unlike epithelial ovarian cancer cells, does not
express mRNA or protein for IL-6, M-CSF, or TNF (Roby
& Terranova, 1989; Motro et al., 1990). Dysregulated
cytokine production could occur during the transformation
of normal epithelium to malignant cells or due to oncogene
activation (Demetri et al., 1990), and subsequent constitutive
expression of cytokines and cytokine receptors may lead to
autocrine growth stimulation of tumour cells or to modula-
tion of their metastatic potential. The presence of M-CSF
and c-fms like receptor tanscripts, particularly in poorly
differentiated ovarian tumours suggest that M-CSF may be
an autocrine growth factor in some ovarian cancers. M-CSF
production can be increased by gonadotropins (Bartocci et
al., 1986), and this cytokine may be an important mediator in
the putative tumour promoting role of gonadotropins. The
protective effect of oral contraceptives could be mediated by
decreased M-CSF induction due to feedback inhibition of
gonadotropin release. Reproductive hormone/cytokine interac-
tion may also involve the reported inhibitory effects of
oestrogens on TNF secretion (Ralston et al., 1990). Loss of
oestrogen secretion coupled with high levels of gonadotropin
secretion could perpetuate the induction of TNF in the ovary
via M-CSF, and explain the increased incidence of ovarian
tumours with advancing age. Of relevance to this is the
observation that a high percentage of ovarian cancers have
specific deletions near to, and possibly involving, the oestro-
gen receptor locus on chromosome 6 (Lee et al., 1990).
Cytokines released in the vicinity of the tumour may
induce tumour cytokine production. For example, TNF has
been shown to induce TNF mRNA and protein in epithelial
tumours in vitro and in vivo (Niitsu et al., 1988; Malik &
Balkwill, 1990). Prolonged exposure to TNF led not only to
the development of resistance to TNF, but induced consti-
tutive secretion of TNF by tumour cell lines (Spriggs et al.,
1987). This could be relevant to the observation that tumours
from the more frequently ovulating right ovary have a higher
rate of metastasis at presentation (Cruickshank, 1990), i.e.
these tumours may have acquired the ability to produce TNF
by more frequent exposure to TNF released locally during
the wound healing process after ovulation. A similar
phenomenon could explain the association between the use of
talc and occurrence of ovarian cancer in some studies, as talc
induces granulomatous lesions which are a source of TNF
(Kindler et al., 1989). Alternatively, the invagination of
ovarian surface epithelium that leads to inclusion cyst forma-
tion, may lead to the epithelium being exposed to intra-
ovarian TNF being produced by macrophages and granulosa
cells (Roby & Terranova, 1989).
In conclusion, epithelial ovarian cancers and ovarian
cancer cell lines have been shown to innappropriately elabor-
ate a number of cytokines. These cytokines can potentially
perpetuate their own biological effects by recruiting cytokine
producing host cells and inducing further cytokine produc-
tion. Recent experimental evidence indicates a potential role
for at least two cytokines (TNF and IL-1) in the promotion
of ovarian cancer metastasis, and two others (M-CSF and
the ligand for the c-erbB-2 proto-oncogene) as putative auto-
crine growth factors in ovarian cancer. These cell regulatory
molecules may be acting to create a hormone modulated
tumour promoting environment in this disease. If so, future
therapies for ovarian cancer may involve negating the effects
of these cytokines, either by inhibition of cytokine secretion,
inhibition of the recruitment of cytokine producing cells, or
treatment with specific cytokine antagonists.
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